Get the Stockscreener App
41.53
1.79%
0.73
Pre-market:
41.01
-0.52
-1.25%
Omnicell Inc stock is traded at $41.53, with a volume of 444.66K.
It is up +1.79% in the last 24 hours and down -11.05% over the past month.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
See More
Previous Close:
$40.80
Open:
$41.34
24h Volume:
444.66K
Relative Volume:
0.69
Market Cap:
$1.86B
Revenue:
$1.15B
Net Income/Loss:
$23.09M
P/E Ratio:
83.06
EPS:
0.5
Net Cash Flow:
$89.18M
1W Performance:
+0.39%
1M Performance:
-11.05%
6M Performance:
+25.39%
1Y Performance:
+11.07%
1-Day Range:
$40.99
$41.95
1-Week Range:
$39.97
$42.60
52-Week Range:
$22.66
$55.00
Omnicell Inc Stock (OMCL) Company Profile
Name
Omnicell Inc
Sector
Industry
Phone
(877) 415-9990
Address
4220 NORTH FREEWAY, FORT WORTH
Compare OMCL vs VEEV, TEM, BTSG, HQY, WAY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMCL
Omnicell Inc
|
41.53 | 1.83B | 1.15B | 23.09M | 89.18M | 0.50 |
|
VEEV
Veeva Systems Inc
|
188.48 | 30.56B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
51.29 | 9.19B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
41.96 | 7.33B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
81.15 | 6.87B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
26.93 | 5.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Omnicell Inc Stock (OMCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-26 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-08-26 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| May-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-03-24 | Initiated | Barclays | Underweight |
| Nov-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-03-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-11-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Sep-26-23 | Reiterated | Wells Fargo | Underweight |
| Aug-02-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-23 | Downgrade | Wells Fargo | Overweight → Underweight |
| Feb-27-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-03-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-09-22 | Initiated | BofA Securities | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Mkt Perform |
| Dec-06-21 | Resumed | Wells Fargo | Overweight |
| Jun-09-21 | Initiated | JP Morgan | Neutral |
| May-24-21 | Initiated | BTIG Research | Buy |
| Feb-02-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-20 | Initiated | Berenberg | Buy |
| Dec-03-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Feb-07-20 | Reiterated | Dougherty & Company | Buy |
| Nov-21-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-19 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-07-19 | Reiterated | Dougherty & Company | Buy |
| Jun-29-18 | Resumed | The Benchmark Company | Buy |
| Sep-05-17 | Reiterated | The Benchmark Company | Buy |
| Jul-28-17 | Reiterated | Dougherty & Company | Buy |
| Apr-21-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-19-17 | Initiated | Dougherty & Company | Buy |
| Dec-06-16 | Reiterated | The Benchmark Company | Buy |
| Jul-07-16 | Reiterated | FBR Capital | Outperform |
| Mar-21-16 | Reiterated | Topeka Capital Markets | Buy |
| Jan-07-16 | Initiated | The Benchmark Company | Buy |
| Nov-16-15 | Reiterated | Topeka Capital Markets | Buy |
| Oct-30-15 | Reiterated | FBR Capital | Outperform |
| Sep-28-15 | Upgrade | Sidoti | Neutral → Buy |
| Jul-31-15 | Reiterated | Topeka Capital Markets | Buy |
View All
Omnicell Inc Stock (OMCL) Latest News
How The Titan XT Cycle Is Rewriting The Omnicell (OMCL) Investment Story - Yahoo Finance
Will Strong Q4 Beat and Software Pivot Change Omnicell's (OMCL) Investment Narrative? - Yahoo Finance
Omnicell, Inc. $OMCL Shares Sold by JPMorgan Chase & Co. - MarketBeat
Omnicell Stock Analysis: Strong Performance vs. Long-Term ConcernsNews and Statistics - IndexBox
OMCL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Omnicell, Inc. (OMCL) Stock Analysis: Strong Buy Ratings And Nearly 40% Upside Potential - DirectorsTalk Interviews
Vanguard Group Inc. Has $170.89 Million Holdings in Omnicell, Inc. $OMCL - MarketBeat
Roubaix Capital LLC Purchases Shares of 76,383 Omnicell, Inc. $OMCL - MarketBeat
3 Reasons to Avoid OMCL and 1 Stock to Buy Instead - Finviz
What is Zacks Research's Estimate for Omnicell Q1 Earnings? - MarketBeat
Dividend Watch: Whats the fair value of Omnicell Inc stockEarnings Overview Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Omnicell, Inc. (OMCL): A Bull Case Theory - Insider Monkey
Should Omnicell’s Shift Toward Software and Services Require Action From Omnicell (OMCL) Investors? - Sahm
OMCL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
What is Zacks Research's Estimate for Omnicell Q3 Earnings? - MarketBeat
Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Decoding Omnicell Inc (OMCL): A Strategic SWOT Insight - GuruFocus
(OMCL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Omnicell, Inc. (OMCL) Investor Outlook: Examining a 45% Potential Upside Amid Healthcare Innovation - DirectorsTalk Interviews
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know - Finviz
Healthcare Inventory Management Market Hits New High | Major - openPR.com
Omnicell Inc (OMCL) Trading 3.26% Higher on Feb 20 - GuruFocus
Omnicell (OMCL) VP reports tax withholding and ESPP share purchase - Stock Titan
Omnicell (OMCL) insider plans Rule 144 sale of 4,243 vested shares - Stock Titan
Hospital Robotics (Logistics and Pharmacy) Market to Reach USD - openPR.com
Does Omnicell’s Profit Squeeze Amid Higher Sales and 2026 Outlook Change The Bull Case For OMCL? - simplywall.st
Merger Talk: Is NewAmsterdam Pharma Company NVs ROIC above industry average2025 Technical Overview & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Omnicell, Inc. (NASDAQ:OMCL) Sees Large Drop in Short Interest - MarketBeat
Responsive Playbooks and the OMCL Inflection - Stock Traders Daily
Growth Report: How volatile is Omnicell Inc stock2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Reasons to add Omnicell stock to your portfolio right now - MSN
Smart Medicine Compounding Robot Market Is Going to Boom | ARxIUM - openPR.com
Omnicell (OMCL) Is Down 19.0% After Profit Squeeze Despite Solid 2026 Revenue OutlookWhat's Changed - Yahoo Finance
Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues As Shares Take 26% Pounding - 富途牛牛
Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge - simplywall.st
The Top 5 Analyst Questions From Omnicell's Q4 Earnings Call - Finviz
The Top 5 Analyst Questions From Omnicell’s Q4 Earnings Call - Yahoo Finance
Omnicell (NASDAQ:OMCL) Cut to Strong Sell at Zacks Research - MarketBeat
Omnicell, Inc. (OMCL) Stock Analysis: Unpacking a Potential 57% Upside in Healthcare Automation - DirectorsTalk Interviews
Omnicell (OMCL) Q4 2025 Earnings Call Transcript - AOL.com
Omnicell: Solid Execution and Strategic Promise Offset by Near-Term Profitability Pressures and Premium Valuation (Hold Rating Maintained) - TipRanks
Omnicell, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:OMCL) 2026-02-08 - Seeking Alpha
Omnicell upgraded at BofA on buying opportunity ahead of Q4 results - MSN
Omnicell (OMCL) Margin Squeeze To 0.2% Net Profit Tests Bullish Recovery Narratives - Sahm
Analysts Conflicted on These Healthcare Names: Cigna (CI), Hims & Hers Health (HIMS) and Omnicell (OMCL) - The Globe and Mail
Omnicell (NASDAQ:OMCL) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Omnicell Earnings Call: Growth Intact, Margins Under Strain - The Globe and Mail
Omnicell, Inc. (NASDAQ:OMCL) Q4 2025 Earnings Call Transcript - Insider Monkey
Omnicell (NASDAQ:OMCL) Stock Price Down 4.2% on Disappointing Earnings - MarketBeat
Analyst Jessica Tassan Lowers Omnicell (OMCL) Price Target to $4 - GuruFocus
Omnicell Q4 2025 Earnings: Stock Dives on Missed EPS, 2026 GuidanceNews and Statistics - IndexBox
Omnicell Inc Stock (OMCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):